The DOI matches its Crossref record.
Randomized Comparison of Linezolid (PNU-100766) versus Oxacillin-Dicloxacillin for Treatment of Complicated Skin and Soft Tissue Infections
Open accessAbstract
This randomized, double-blind, multicenter trial compared the efficacy and safety of linezolid, an oxazolidinone, with those of oxacillin-dicloxacillin in patients with complicated skin and soft tissue infections. A total of 826 hospitalized adult patients were randomized to receive linezolid (600 mg intravenously [i.v.]) every 12 h or oxacillin (2 g i.v.) every 6 h; following sufficient clinical improvement, patients were switched to the respective oral agents (linezolid [600 mg orally] every 12 h or dicloxacillin [500 mg orally] every 6 hours). Primary efficacy variables were clinical cure rates in both the intent-to-treat (ITT) population and clinically evaluable (CE) patients and microbiological success rate in microbiologically evaluable (ME) patients. Safety and tolerability were evaluated in the ITT population. Demographics and baseline characteristics were similar across treatment groups in the 819 ITT patients. In the ITT population, the clinical cure rates were 69.8 and 64.9% in the linezolid and oxacillin-dicloxacillin groups, respectively (P= 0.141; 95% confidence interval −1.58 to 11.25). In 298 CE linezolid-treated patients, the clinical cure rate was 88.6%, compared with a cure rate of 85.8% in 302 CE patients who received oxacillin-dicloxacillin. In 143 ME linezolid-treated patients, the microbiological success rate was 88.1%, compared with a success rate of 86.1% in 151 ME patients who received oxacillin-dicloxacillin. Both agents were well tolerated; most adverse events were of mild-to-moderate intensity. No serious drug-related adverse events were reported in the linezolid group. These data support the use of linezolid for the treatment of adults with complicated skin and soft tissue infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
Self-citationStevens, D. L., Herr, D., Lampiris, H., Hunt, J. L., Batts, D. H., Hafkin, B., & the Linezolid MRSA Study Group (2002) · Clinical Infectious Diseases · doi:10.1086/340353 · Cited by 506
Self-citationLinezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections
Weigelt, J., Itani, K., Stevens, D., Lau, W., Dryden, M., & Knirsch, C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2260-2266.2005 · Cited by 457
Self-citationLinezolid: The First Oxazolidinone Antimicrobial
Moellering, R. C. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00015 · Cited by 455
Metadata
- Authors
- Stevens, D. L., Smith, L. G., Bruss, J. B., McConnell-Martin, M. A., Duvall, S. E., Todd, W. M., & Hafkin, B.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2000-12
- Volume
- 44
- Issue
- 12
- Pages
- 3408-3413
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1985261796
- Cited by
- 242
- References
- 0
- FWCI
- 18.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Comparison of Linezolid (PNU-100766) versus Oxacillin-Dicloxacillin for Treatment of Complicated Skin and Soft Tissue Infections. https://app.cochat.ai/papers/10.1128/aac.44.12.3408-3413.2000
- The paper
- Stevens, D. L., Smith, L. G., Bruss, J. B., McConnell-Martin, M. A., Duvall, S. E., Todd, W. M., & Hafkin, B. (2000). Randomized Comparison of Linezolid (PNU-100766) versus Oxacillin-Dicloxacillin for Treatment of Complicated Skin and Soft Tissue Infections. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.44.12.3408-3413.2000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.